Home
    • Plans Blog Contact
    Bespoke Extracts, Inc. logo

    Bespoke Extracts, Inc.

    BSPK
    Last price US$0.0007
    Market cap US$7800.0
    12M price change N/A
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Zoetis IncZTS Industry peer Amphastar PAMPH Industry peer Prestige Consumer HealthcarePBH Industry peer IQVIA Holdings IncIQV Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Bespoke Extracts, Inc. Overview

    Industry: Drug Manufacturers Specialty & Generic

    Sector: Healthcare

    Bespoke Extracts, Inc. provides hemp-derived cannabidiol (CBD) products. The company offers CBD formulations, including manuka honey and in the form of lotions and balms; and markets CBD extracts in capsule form, topicals, and gummies. It offers its products through its direct to consumers e-commerce store bespokeextracts.com. The company was formerly known as DiMi Telematics International, Inc. and changed its name to Bespoke Extracts, Inc. in March 2017. The company is headquartered in Denver, Colorado. Bespoke Extracts, Inc. provides hemp-derived cannabidiol (CBD) products. The company offers CBD formulations, including manuka honey and in the form of lotions and balms; and markets CBD extracts in capsule form, topicals, and gummies. It offers its products through its direct to consumers e-commerc Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Bespoke Extracts, Inc. into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Nov 19, 2025

    Quarterly result summary

    Revenue was $467.9M (+68.6% YoY). Net loss was -$0.1M.

    Revenue $467.9M +68.6% YoY
    Net loss -$0.1M reported

    What changed

    • Revenue +68.6% YoY to $467.9M.

    Guidance / outlook

    The company expects to maintain approximately 50% blended gross margins across product lines through disciplined cost management and increased production throughput.

    Earnings material Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing CURRENT REPORT Nov 19, 2025 SEC filing QUARTERLY REPORT Nov 12, 2025 SEC filing QUARTERLY REPORT Aug 27, 2025 SEC filing CURRENT REPORT Jul 07, 2025 Earnings release PRESS RELEASE DATED JUNE 30, 2025 Jul 07, 2025 SEC filing QUARTERLY REPORT Jun 30, 2025 SEC filing ANNUAL REPORT Apr 21, 2025 SEC filing QUARTERLY REPORT Nov 13, 2024 SEC filing QUARTERLY REPORT Oct 08, 2024

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    No qualified company news in the last 14 days

    No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.

    Earnings Per Share

    Score 0.00/5
    Bespoke Extracts, Inc. earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Return on Equity

    Score 3.71/5
    Bespoke Extracts, Inc. stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Bespoke Extr... BSPK US$7800
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 3.73/5
    Bespoke Extracts, Inc. commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Bespoke Extr... BSPK US$7800
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Leverage

    Score 4.76/5
    Bespoke Extracts, Inc. attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Bespoke Extr... BSPK US$7800
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Bespoke Extracts, Inc. logo

    Bespoke Extracts, Inc.

    US$0.0007

    US$7800.0

    -99.42%

    N/A